Major adverse effects from systemic drugs: Defining the risks

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This review covers the most important adverse effects from systemic drugs prescribed by dermatologists. The emphasis is on major adverse effects from these drugs that are either life-threatening or more commonly may lead to significant, irreversible morbidity. In descending order of relative risk for a fatal outcome or persistent morbidity, the major adverse effects discussed are dapsone agranulocytosis, methotrexate pancytopenia, retinoid teratogenicity, corticosteroid osteonecrosis, immunosuppression carcinogenesis, methotrexate hepatotoxicity, cyclosporine nephrotoxicity, azathioprine agranulocytosis and pancytopenia, corticosteroid osteoporosis, retinoid bone toxicity, corticosteroid hypothalamic—pituitary—adrenal axis suppression, and corticosteroid growth suppression. The great majority of these adverse effects are preventable, are diagnosable at an early, reversible stage, or can be readily managed should the complication occur. Furthermore, after carefully reviewing reports on the occasional fatal outcomes from the adverse effects discussed in this review, I believe virtually all deaths could have been prevented with careful attention to definable risk factors and with proper monitoring measures. Overall, the goal of this review is to bring clinicians to a proper level of concern regarding the risks from these drugs, while allowing safe use of potentially risky systemic drugs to the benefit of patients with serious and important skin conditions.

Original languageEnglish (US)
Pages (from-to)6-38
Number of pages33
JournalCurrent Problems in Dermatology (United States)
Volume7
Issue number1
DOIs
StatePublished - 1995

Fingerprint

Adrenal Cortex Hormones
Pancytopenia
Agranulocytosis
Fatal Outcome
Retinoids
Methotrexate
Pharmaceutical Preparations
Morbidity
Dapsone
Osteonecrosis
Azathioprine
Immunosuppression
Cyclosporine
Osteoporosis
Carcinogenesis
Bone and Bones
Skin
Growth

ASJC Scopus subject areas

  • Dermatology

Cite this

Major adverse effects from systemic drugs : Defining the risks. / Wolverton, Stephen.

In: Current Problems in Dermatology (United States), Vol. 7, No. 1, 1995, p. 6-38.

Research output: Contribution to journalArticle

@article{1d123fcaabfe484e8e0e8a12f5e67098,
title = "Major adverse effects from systemic drugs: Defining the risks",
abstract = "This review covers the most important adverse effects from systemic drugs prescribed by dermatologists. The emphasis is on major adverse effects from these drugs that are either life-threatening or more commonly may lead to significant, irreversible morbidity. In descending order of relative risk for a fatal outcome or persistent morbidity, the major adverse effects discussed are dapsone agranulocytosis, methotrexate pancytopenia, retinoid teratogenicity, corticosteroid osteonecrosis, immunosuppression carcinogenesis, methotrexate hepatotoxicity, cyclosporine nephrotoxicity, azathioprine agranulocytosis and pancytopenia, corticosteroid osteoporosis, retinoid bone toxicity, corticosteroid hypothalamic—pituitary—adrenal axis suppression, and corticosteroid growth suppression. The great majority of these adverse effects are preventable, are diagnosable at an early, reversible stage, or can be readily managed should the complication occur. Furthermore, after carefully reviewing reports on the occasional fatal outcomes from the adverse effects discussed in this review, I believe virtually all deaths could have been prevented with careful attention to definable risk factors and with proper monitoring measures. Overall, the goal of this review is to bring clinicians to a proper level of concern regarding the risks from these drugs, while allowing safe use of potentially risky systemic drugs to the benefit of patients with serious and important skin conditions.",
author = "Stephen Wolverton",
year = "1995",
doi = "10.1016/S1040-0486(09)80019-7",
language = "English (US)",
volume = "7",
pages = "6--38",
journal = "Current Problems in Dermatology",
issn = "1040-0486",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Major adverse effects from systemic drugs

T2 - Defining the risks

AU - Wolverton, Stephen

PY - 1995

Y1 - 1995

N2 - This review covers the most important adverse effects from systemic drugs prescribed by dermatologists. The emphasis is on major adverse effects from these drugs that are either life-threatening or more commonly may lead to significant, irreversible morbidity. In descending order of relative risk for a fatal outcome or persistent morbidity, the major adverse effects discussed are dapsone agranulocytosis, methotrexate pancytopenia, retinoid teratogenicity, corticosteroid osteonecrosis, immunosuppression carcinogenesis, methotrexate hepatotoxicity, cyclosporine nephrotoxicity, azathioprine agranulocytosis and pancytopenia, corticosteroid osteoporosis, retinoid bone toxicity, corticosteroid hypothalamic—pituitary—adrenal axis suppression, and corticosteroid growth suppression. The great majority of these adverse effects are preventable, are diagnosable at an early, reversible stage, or can be readily managed should the complication occur. Furthermore, after carefully reviewing reports on the occasional fatal outcomes from the adverse effects discussed in this review, I believe virtually all deaths could have been prevented with careful attention to definable risk factors and with proper monitoring measures. Overall, the goal of this review is to bring clinicians to a proper level of concern regarding the risks from these drugs, while allowing safe use of potentially risky systemic drugs to the benefit of patients with serious and important skin conditions.

AB - This review covers the most important adverse effects from systemic drugs prescribed by dermatologists. The emphasis is on major adverse effects from these drugs that are either life-threatening or more commonly may lead to significant, irreversible morbidity. In descending order of relative risk for a fatal outcome or persistent morbidity, the major adverse effects discussed are dapsone agranulocytosis, methotrexate pancytopenia, retinoid teratogenicity, corticosteroid osteonecrosis, immunosuppression carcinogenesis, methotrexate hepatotoxicity, cyclosporine nephrotoxicity, azathioprine agranulocytosis and pancytopenia, corticosteroid osteoporosis, retinoid bone toxicity, corticosteroid hypothalamic—pituitary—adrenal axis suppression, and corticosteroid growth suppression. The great majority of these adverse effects are preventable, are diagnosable at an early, reversible stage, or can be readily managed should the complication occur. Furthermore, after carefully reviewing reports on the occasional fatal outcomes from the adverse effects discussed in this review, I believe virtually all deaths could have been prevented with careful attention to definable risk factors and with proper monitoring measures. Overall, the goal of this review is to bring clinicians to a proper level of concern regarding the risks from these drugs, while allowing safe use of potentially risky systemic drugs to the benefit of patients with serious and important skin conditions.

UR - http://www.scopus.com/inward/record.url?scp=84989820508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989820508&partnerID=8YFLogxK

U2 - 10.1016/S1040-0486(09)80019-7

DO - 10.1016/S1040-0486(09)80019-7

M3 - Article

AN - SCOPUS:84989820508

VL - 7

SP - 6

EP - 38

JO - Current Problems in Dermatology

JF - Current Problems in Dermatology

SN - 1040-0486

IS - 1

ER -